Lipid lowering with PCSK9 reduces the pro-inflammatory phenotype of monocytes
In the high impact European Heart Journal, The AMC group (Bernelot Moens et al) published a European Heart Journal paper on the impact of LDL cholesterol lowering on monocyte phenotype and function in patients with familial hypercholesterolaemia not using statins due to statin-associated muscle symptoms.. This open-access article can be found here (doi:10.1093/eurheartj/ehx002).
The group shows that lipid lowering with PCSK9 reduces the pro-inflammatory phenotype of monocytes without affecting C reactive protein, implying that potent lowering of LDL cholesterol has an anti-inflammatory impact in hypercholesterolemic patients. These data highlight that inflammation is not solely captured by C reactive protein mea
surement and warrant future investigations to assess the role of attenuating cellular inflammation in patients at high cardiovascular risk.